U.S. Food and Drug Administration staff members said on Friday Acadia Pharmaceuticals Inc’s drug to treat psychosis associated with Parkinson’s disease was an effective treatment for the condition.
The drug, Nuplazid, is a new chemical compound and could be the first drug specifically approved in the United States for Parkinson’s disease psychosis (PDP). (1.usa.gov/1PuYUCe)
Parkinson’s disease is typically associated with impaired motor function.
